Details about Aidan Hollis

Access statistics for papers by Aidan Hollis.

Last updated 2022-01-26. Update your information in the RePEc Author Service.

Short-id: pho163

Working Papers

2010

1. Generic drug pricing in Canada: components of the value-chain
   Working Papers, Department of Economics, University of Calgary
2. New Approaches to Rewarding Pharmaceutical Innovation
   Levine's Bibliography, UCLA Department of Economics View citations (3)

2008

3. Privacy, Driving Data and Automobile Insurance: An Economic Analysis
   Working Papers, Department of Economics, University of Calgary
   Also in MPRA Paper, University Library of Munich, Germany (2007) View citations (4)

1997

4. Complementarity, Competition and Institutional Development: The Irish Loan Funds through Three Centuries
   Economic History, University Library of Munich, Germany View citations (4)
5. Microcredit in Pre-Famine Ireland
   Economic History, University Library of Munich, Germany View citations (3)
   See also Journal Article in Explorations in Economic History (1998)

1996

6. A Contractual Approach to the Gray Market
   Working Papers, University of Toronto, Department of Economics View citations (1)
   See also Journal Article in International Review of Law and Economics (1999)
7. Exclusivity Restrictions in Markets with Adverse Selection: The Case of Extended Warranties
   Working Papers, University of Toronto, Department of Economics
8. Subsidizing the Competition
   Working Papers, University of Toronto, Department of Economics
9. The Evolution of A Microcredit Institution: The Irish Loan Funds, 1720 - 1920
   Working Papers, University of Toronto, Department of Economics View citations (1)

Journal Articles

2021

1. The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications
   Health Economics, 2021, 30, (5), 1139-1151

2020

2. Patient income and health innovation
   Health Economics, 2020, 29, (12), 1795-1803 View citations (1)

2019

3. How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?
   Health Policy, 2019, 123, (12), 1251-1258

2018

4. Making Sure Orphan Drugs Don’t Get Left Behind
   SPP Communique, 2018, 10, (6)

2016

5. Sustainable Financing of Innovative Therapies: A Review of Approaches
   PharmacoEconomics, 2016, 34, (10), 971-980 View citations (1)

2015

6. Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics
   International Journal of the Economics of Business, 2015, 22, (2), 201-217 View citations (3)
7. Price‐cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals
   Health Economics, 2015, 24, (8), 966-977 View citations (4)

2014

8. The path of least resistance: Paying for antibiotics in non-human uses
   Health Policy, 2014, 118, (2), 264-270 View citations (2)

2010

9. The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers
   Energy Policy, 2010, 38, (7), 3837-3846 View citations (34)

2009

10. Generic Drug Pricing and Procurement: A Policy for Alberta
    SPP Research Papers, 2009, 2, (1) View citations (2)

2007

11. Preliminary Injunctions and Damage Rules in Patent Law
    Journal of Economics & Management Strategy, 2007, 16, (2), 385-405 View citations (8)
12. The Role of Local Depositors in Controlling Expenses in Small‐Scale Financial Intermediation: An Empirical Analysis
    Economica, 2007, 74, (296), 713-735 View citations (5)

2005

13. Governance of electricity transmission systems
    Energy Economics, 2005, 27, (2), 237-255 View citations (9)
14. How do Brands’ “Own Generics” Affect Pharmaceutical Prices?
    Review of Industrial Organization, 2005, 27, (4), 329-350 View citations (8)

2004

15. A National Formulary for Canada
    Canadian Public Policy, 2004, 30, (4), 445-452
16. Competition policy in open economies
    International Economic Journal, 2004, 18, (2), 179-193 View citations (3)
17. Microfinance and Famine: The Irish Loan Funds during the Great Famine
    World Development, 2004, 32, (9), 1509-1523 View citations (6)

2003

18. Industrial Concentration, Output, and Trade: An Empirical Exploration
    Review of Industrial Organization, 2003, 22, (2), 103-119 View citations (7)
19. The Anti-Competitive Effects of Brand-Controlled "Pseudo- Generics" in the Canadian Pharmaceutical Market
    Canadian Public Policy, 2003, 29, (1), 21-31 View citations (14)

2002

20. Strategic Implications of Learning by Doing
    International Journal of the Economics of Business, 2002, 9, (2), 157-174 View citations (4)
21. The importance of being first: evidence from Canadian generic pharmaceuticals
    Health Economics, 2002, 11, (8), 723-734 View citations (23)

2001

22. Co-authorship and the output of academic economists
    Labour Economics, 2001, 8, (4), 503-530 View citations (111)
23. The life-cycle of a microfinance institution: the Irish loan funds
    Journal of Economic Behavior & Organization, 2001, 46, (3), 291-311 View citations (11)

1999

24. A contractual approach to the gray market
    International Review of Law and Economics, 1999, 19, (1), 1-21 View citations (22)
    See also Working Paper (1996)

1998

25. Microcredit in Prefamine Ireland
    Explorations in Economic History, 1998, 35, (4), 347-380 View citations (13)
    See also Working Paper (1997)
26. Microcredit: What can we learn from the past?
    World Development, 1998, 26, (10), 1875-1891 View citations (42)